COMMUNIQUÉS West-GlobeNewswire

-
Genfit: GENFIT ANNONCE LA SUSPENSION DU COURS DE SES ACTIONS ET DE SES OCEANES SUR EURONEXT PARIS ET EURONEXT ACCESS
27/03/2019 -
Aino Health AB (publ): Aino Health and Veritas Pension Insurance will launch Work Ability Support Service Center
27/03/2019 -
Genfit: GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
27/03/2019 -
Genfit: GENFIT annonce le succès de son introduction en bourse sur le Nasdaq dans le cadre d’une offre globale d’American Depositary Shares aux États-Unis et d’un placement privé d’actions
27/03/2019 -
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
27/03/2019 -
MyoKardia Announces Pricing of Public Offering of Common Stock
26/03/2019 -
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
26/03/2019 -
Harvard Bioscience To Showcase Products at Experimental Biology 2019
26/03/2019 -
Lutronic Vision Engages World Renowned Retina Expert for R:GEN™ Pilot AMD Clinical Study
26/03/2019 -
Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
26/03/2019 -
ImmuCell Corporation Announces Commencement of Public Offering of Common Stock
26/03/2019 -
Selecta Biosciences Announces New Employment Inducement Grant
26/03/2019 -
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
26/03/2019 -
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
26/03/2019 -
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
26/03/2019 -
Guerbet: 2018 annual results
26/03/2019 -
GUERBET: Résultats annuels 2018
26/03/2019 -
I-PEN® Osmolarity System Now Available in Brazil Through Partnership with DryCom
26/03/2019 -
OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets
26/03/2019
Pages